Search results
Added:
6 months ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights…
View more
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more
Prioritising Risk in CAD: A Patient-First Discussion
Video Series
Start date:
Dec 14, 2023
This live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), will demonstrate how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Join key opinion leadersProf Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese (University of Sassari,…
View more
Added:
1 year ago
Added:
2 months ago
Added:
2 days ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 week ago
AHA 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses targeting…
View more
Added:
1 month ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
2 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient…
View more